Santhera Pharmaceuticals Holding AG (SW:SANN) — Stock Price

CHF16.40 CHF
▲ 3.54% today

Santhera Pharmaceuticals Holding AG (SW:SANN) is currently trading at CHF16.40 CHF, up 3.54% today. Over the past 52 weeks, shares have ranged between CHF9.58 and CHF18.54. This page tracks Santhera Pharmaceuticals Holding AG's live share price on the SW exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see market value of Santhera Pharmaceuticals Holding AG.

Santhera Pharmaceuticals Holding AG (SANN) Stock Price Chart — Daily History & Trading Volume

The chart below tracks Santhera Pharmaceuticals Holding AG's daily closing share price and trading volume on the SW exchange over the past year, giving a clear view of recent price momentum and liquidity.

Santhera Pharmaceuticals Holding AG Income Statement — Revenue, Profit & Earnings by Year

Santhera Pharmaceuticals Holding AG's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.

Fiscal Year 20252024202320222021
Total Revenue CHF77.19 Million CHF39.12 Million CHF103.41 Million CHF7.47 Million CHF-1.59 Million
Cost of Revenue CHF62.72 Million CHF15.53 Million CHF3.23 Million CHF3.59 Million CHF3.77 Million
Gross Profit CHF14.47 Million CHF22.96 Million CHF100.18 Million CHF3.88 Million CHF-5.36 Million
Research & Development CHF22.22 Million CHF26.47 Million CHF18.67 Million CHF30.54 Million CHF29.71 Million
SG&A CHF30.77 Million CHF19.48 Million CHF21.18 Million CHF14.56 Million CHF12.72 Million
Total Operating Expenses CHF52.28 Million CHF56.69 Million CHF31.34 Million CHF55.86 Million CHF51.53 Million
Operating Income CHF-37.82 Million CHF-33.38 Million CHF68.84 Million CHF-51.98 Million CHF-56.89 Million
EBITDA CHF-32.13 Million CHF-15.89 Million CHF79.17 Million CHF-46.78 Million CHF-34.57 Million
EBIT CHF-37.82 Million CHF-21.53 Million CHF76.13 Million CHF-50.43 Million CHF-38.29 Million
Interest Expense CHF11.56 Million CHF20.17 Million CHF21.31 Million CHF20.19 Million CHF16.42 Million
Income Before Tax CHF-49.05 Million CHF-41.66 Million CHF54.82 Million CHF-70.62 Million CHF-54.72 Million
Income Tax Expense CHF185.00K CHF312.00K CHF38.00K CHF460.00K CHF809.00K
Net Income CHF-49.24 Million CHF-41.97 Million CHF54.78 Million CHF-71.08 Million CHF-55.53 Million

Santhera Pharmaceuticals Holding AG Balance Sheet — Assets, Liabilities & Shareholder Equity

The balance sheet below summarizes Santhera Pharmaceuticals Holding AG's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.

Fiscal Year 20252024202320222021
Total Assets CHF148.09 Million CHF152.49 Million CHF109.63 Million CHF63.73 Million CHF91.12 Million
Total Current Assets CHF80.24 Million CHF75.81 Million CHF34.66 Million CHF3.06 Million CHF24.64 Million
Cash & Equivalents CHF22.59 Million CHF21.84 Million CHF21.21 Million
Short-term Investments
Net Receivables CHF26.04 Million CHF13.88 Million CHF440.00K CHF1.09 Million CHF1.94 Million
Inventory CHF24.87 Million CHF17.53 Million CHF1.81 Million CHF108.00K CHF428.00K
Property, Plant & Equipment CHF2.57 Million CHF582.00K CHF1.32 Million
Goodwill
Total Liabilities CHF159.90 Million CHF124.79 Million CHF49.69 Million CHF107.41 Million CHF89.79 Million
Total Current Liabilities CHF62.17 Million CHF46.14 Million CHF44.31 Million CHF49.41 Million CHF32.78 Million
Long-term Debt CHF32.73 Million CHF31.73 Million CHF0.00 CHF21.08 Million CHF25.80 Million
Net Debt CHF75.33 Million CHF248.00K CHF-7.34 Million CHF43.08 Million CHF21.77 Million
Total Stockholder Equity CHF-11.82 Million CHF27.70 Million CHF59.94 Million CHF-43.69 Million CHF1.33 Million
Retained Earnings CHF-663.93 Million CHF-614.69 Million CHF-572.72 Million CHF-627.50 Million CHF-556.42 Million

Santhera Pharmaceuticals Holding AG Cash Flow Statement — Operating, Investing & Financing Activities

This cash flow statement breaks down how Santhera Pharmaceuticals Holding AG generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.

Fiscal Year 20252024202320222021
Operating Cash Flow CHF-34.76 Million CHF-35.53 Million CHF47.27 Million CHF-29.84 Million CHF-37.36 Million
Capital Expenditures CHF52.00K CHF151.00K CHF23.74 Million CHF3.96 Million CHF15.00K
Free Cash Flow CHF-34.81 Million CHF-35.68 Million CHF23.53 Million CHF-33.80 Million CHF-37.37 Million
Investing Cash Flow CHF-122.00K CHF-61.00K CHF-18.04 Million CHF-3.93 Million CHF69.00K
Financing Cash Flow CHF16.38 Million CHF46.08 Million CHF-171.00K CHF13.99 Million CHF46.02 Million
Dividends Paid CHF32.66 Million
Stock-Based Compensation CHF4.25 Million CHF3.97 Million CHF5.99 Million CHF5.45 Million CHF2.76 Million
Depreciation CHF5.69 Million CHF5.65 Million CHF3.04 Million CHF9.86 Million CHF3.72 Million
Change in Cash CHF-18.48 Million CHF10.55 Million CHF29.02 Million CHF-19.86 Million CHF8.80 Million

Santhera Pharmaceuticals Holding AG Earnings History — EPS Actual vs. Analyst Estimates

Track Santhera Pharmaceuticals Holding AG's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.

Report Date EPS Actual EPS Estimate Surprise
Apr 27, 2026 0.16
Dec 31, 2025 0.94
Dec 10, 2025 -0.37 -0.26 -42.31%
Sep 10, 2025 -0.60 -0.60 +0.00%
Apr 29, 2025 -2.34 -0.83 -181.93%
Dec 31, 2024 -0.83
Dec 11, 2024 -0.90 -0.90 +0.00%
Sep 12, 2024 -1.35 -0.94 -43.62%